Market Overview

GW Pharma Shares Double Following Positive Epidiolex Trial

Share:
GW Pharma Shares Double Following Positive Epidiolex Trial
Related GWPH
The 2018 Farm Bill Vote: What You Need To Know
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
B. Riley FBR likes NASH players Viking Therapeutics and Galmed Pharma in premarket analyst action (Seeking Alpha)

Shares of GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) are up nearly 120 percent in early Monday trading after the company announced positive Phase III data on Epidiolex. The study found that the drug significantly reduced seizures in children suffering from Dravet Syndrome, a condition for which there are currently no FDA-approved treatments.

“The results of this Epidiolex pivotal trial are important and exciting as they represent the first placebo-controlled evidence to support the safety and efficacy of pharmaceutical cannabidiol in children with Dravet Syndrome, one of the most severe and difficult-to-treat types of epilepsy,” Dr. Orrin Devinsky said in the company’s press release.

Related Link: 15 Marijuana Stocks To Watch In 2015: Where Are They Now?

“The data suggests that they could file on the basis of this study rather than wait for the next three, which, if they do, could drive the price even higher,” Alan Brochstein, author of 420 Investor, told Benzinga.

Most marijuana stocks were down significantly in 2015, but Brochstein believes that the big news for GW Pharmaceuticals might provide a sentiment boost for the whole marijuana industry.

“With that said, this is a clinical trial and not a drug approval, so there remains considerable binary risk, as most of the value of the company is in this key drug, Epidiolex,” he cautioned.

Even with Monday morning’s huge surge, GW Pharmaceuticals is still down 13.7 percent over the past year.

Disclosure: The author holds no position in the stocks mentioned.

Image Credit: Public Domain

Latest Ratings for GWPH

DateFirmActionFromTo
Dec 2018OppenheimerInitiates Coverage OnPerform
Dec 2018Cantor FitzgeraldMaintainsOverweightOverweight
Nov 2018Leerink SwannInitiates Coverage OnOutperform

View More Analyst Ratings for GWPH
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas News Health Care Topics Events Markets Best of Benzinga

 

Related Articles (GWPH)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
MOSJP MorganDowngrades33.0
BACKeefe Bruyette & WoodsDowngrades29.0
AMTMorgan StanleyDowngrades170.0
EBAYMorgan StanleyDowngrades33.0
UNITMorgan StanleyDowngrades16.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Watch Hotel Sector Following News Of New Bid For Starwood

Benzinga's Volume Movers